In a recent study, decreased Mfn2 expression during the progression of AD was shown to be partly due to suppression by microRNA‐195 (miR‐195), and inhibition of this microRNA could prevent the decline in Mfn2 levels, thus providing a potential new therapeutic strategy for AD (Zhang et al.,2016). The gene discussed is MFN2; the disease is Alzheimer disease.